Ruxolitinib deuterated

Drug Profile

Ruxolitinib deuterated

Alternative Names: CTP-543; Deuterated ruxolitinib; Deuterium ruxolitinib analogue - Concert Pharmaceuticals

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Concert Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Cyclopentanes; Nitriles; Organic deuterium compounds; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Alopecia areata

Most Recent Events

  • 11 Jul 2017 US FDA removes clinical hold from a phase IIa trial for Alopecia areata
  • 30 Jun 2017 Concert Pharmaceuticals files a petition for a Post Grant Review with the Patent Trial and Appeal Board to challenge validity of a patent covering deuterated ruxolitinib analogues in USA
  • 17 May 2017 US FDA places clinical hold on a phase IIa trial for Alopecia areata
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top